Please login to the form below

Not currently logged in
Email:
Password:

J&J’s clinical research neuroscience director joins MedAvante

Dr Michael Ropacki becomes head of R&D at the clinical data service

MedAvante Dr Michael RopackiGlobal clinical data services company MedAvante has appointed Dr Michael Ropacki as vice president of research and development.

Dr Ropacki joins MedAvante from Johnson & Johnson, where he served as clinical research neuroscience director in its Janssen research and development arm.

Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013.

He also brings experience as associate director and principal clinical scientist at Johnson & Johnson's biotech Centocor, which he first joined as a clinical scientist in 2004.

Paul Gilbert, MedAvante's chief executive officer, said: “Michael Ropacki is widely recognised for the groundbreaking trial methodology he has implemented for registries and prospective cohort studies.

“He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition to MedAvante's scientific leadership team.”

24th February 2017

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics